Enfortumab vedotin Active Not Recruiting Phase 2 Trials for Metastatic Urothelial Cancer Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Active Not Recruiting | Treatment | 2 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT04995419 | A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy |